Cargando…
Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function
OBJECTIVE: Fibrotic organ responses have recently been identified as long-term complications in diabetes. Indeed, insulin resistance and aberrant hepatic lipid accumulation represent driving features of progressive non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis and non-alco...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034319/ https://www.ncbi.nlm.nih.gov/pubmed/35378329 http://dx.doi.org/10.1016/j.molmet.2022.101487 |
_version_ | 1784693088628768768 |
---|---|
author | Wolff, Gretchen Sakurai, Minako Mhamane, Amit Troullinaki, Maria Maida, Adriano Deligiannis, Ioannis K. Yin, Kelvin Weber, Peter Morgenstern, Jakob Wieder, Annika Kwon, Yun Sekar, Revathi Zeigerer, Anja Roden, Michael Blüher, Matthias Volk, Nadine Poth, Tanja Hackert, Thilo Wiedmann, Lena De Angelis Rigotti, Francesca Rodriguez-Vita, Juan Fischer, Andreas Mukthavaram, Rajesh Limphong, Pattraranee Tachikawa, Kiyoshi Karmali, Priya Payne, Joseph Chivukula, Padmanabh Ekim-Üstünel, Bilgen Martinez-Jimenez, Celia P. Szendrödi, Julia Nawroth, Peter Herzig, Stephan |
author_facet | Wolff, Gretchen Sakurai, Minako Mhamane, Amit Troullinaki, Maria Maida, Adriano Deligiannis, Ioannis K. Yin, Kelvin Weber, Peter Morgenstern, Jakob Wieder, Annika Kwon, Yun Sekar, Revathi Zeigerer, Anja Roden, Michael Blüher, Matthias Volk, Nadine Poth, Tanja Hackert, Thilo Wiedmann, Lena De Angelis Rigotti, Francesca Rodriguez-Vita, Juan Fischer, Andreas Mukthavaram, Rajesh Limphong, Pattraranee Tachikawa, Kiyoshi Karmali, Priya Payne, Joseph Chivukula, Padmanabh Ekim-Üstünel, Bilgen Martinez-Jimenez, Celia P. Szendrödi, Julia Nawroth, Peter Herzig, Stephan |
author_sort | Wolff, Gretchen |
collection | PubMed |
description | OBJECTIVE: Fibrotic organ responses have recently been identified as long-term complications in diabetes. Indeed, insulin resistance and aberrant hepatic lipid accumulation represent driving features of progressive non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis and non-alcoholic steatohepatitis (NASH) to fibrosis. Effective pharmacological regimens to stop progressive liver disease are still lacking to-date. METHODS: Based on our previous discovery of transforming growth factor beta-like stimulated clone (TSC)22D4 as a key driver of insulin resistance and glucose intolerance in obesity and type 2 diabetes, we generated a TSC22D4-hepatocyte specific knockout line (TSC22D4-HepaKO) and exposed mice to control or NASH diet models. Mechanistic insights were generated by metabolic phenotyping and single-nuclei RNA sequencing. RESULTS: Hepatic TSC22D4 expression was significantly correlated with markers of liver disease progression and fibrosis in both murine and human livers. Indeed, hepatic TSC22D4 levels were elevated in human NASH patients as well as in several murine NASH models. Specific genetic deletion of TSC22D4 in hepatocytes led to reduced liver lipid accumulation, improvements in steatosis and inflammation scores and decreased apoptosis in mice fed a lipogenic MCD diet. Single-nuclei RNA sequencing revealed a distinct TSC22D4-dependent gene signature identifying an upregulation of mitochondrial-related processes in hepatocytes upon loss of TSC22D4. An enrichment of genes involved in the TCA cycle, mitochondrial organization, and triglyceride metabolism underscored the hepatocyte-protective phenotype and overall decreased liver damage as seen in mouse models of hepatocyte-selective TSC22D4 loss-of-function. CONCLUSIONS: Together, our data uncover a new connection between targeted depletion of TSC22D4 and intrinsic metabolic processes in progressive liver disease. Hepatocyte-specific reduction of TSC22D4 improves hepatic steatosis and promotes hepatocyte survival via mitochondrial-related mechanisms thus paving the way for targeted therapies. |
format | Online Article Text |
id | pubmed-9034319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90343192022-04-24 Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function Wolff, Gretchen Sakurai, Minako Mhamane, Amit Troullinaki, Maria Maida, Adriano Deligiannis, Ioannis K. Yin, Kelvin Weber, Peter Morgenstern, Jakob Wieder, Annika Kwon, Yun Sekar, Revathi Zeigerer, Anja Roden, Michael Blüher, Matthias Volk, Nadine Poth, Tanja Hackert, Thilo Wiedmann, Lena De Angelis Rigotti, Francesca Rodriguez-Vita, Juan Fischer, Andreas Mukthavaram, Rajesh Limphong, Pattraranee Tachikawa, Kiyoshi Karmali, Priya Payne, Joseph Chivukula, Padmanabh Ekim-Üstünel, Bilgen Martinez-Jimenez, Celia P. Szendrödi, Julia Nawroth, Peter Herzig, Stephan Mol Metab Original Article OBJECTIVE: Fibrotic organ responses have recently been identified as long-term complications in diabetes. Indeed, insulin resistance and aberrant hepatic lipid accumulation represent driving features of progressive non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis and non-alcoholic steatohepatitis (NASH) to fibrosis. Effective pharmacological regimens to stop progressive liver disease are still lacking to-date. METHODS: Based on our previous discovery of transforming growth factor beta-like stimulated clone (TSC)22D4 as a key driver of insulin resistance and glucose intolerance in obesity and type 2 diabetes, we generated a TSC22D4-hepatocyte specific knockout line (TSC22D4-HepaKO) and exposed mice to control or NASH diet models. Mechanistic insights were generated by metabolic phenotyping and single-nuclei RNA sequencing. RESULTS: Hepatic TSC22D4 expression was significantly correlated with markers of liver disease progression and fibrosis in both murine and human livers. Indeed, hepatic TSC22D4 levels were elevated in human NASH patients as well as in several murine NASH models. Specific genetic deletion of TSC22D4 in hepatocytes led to reduced liver lipid accumulation, improvements in steatosis and inflammation scores and decreased apoptosis in mice fed a lipogenic MCD diet. Single-nuclei RNA sequencing revealed a distinct TSC22D4-dependent gene signature identifying an upregulation of mitochondrial-related processes in hepatocytes upon loss of TSC22D4. An enrichment of genes involved in the TCA cycle, mitochondrial organization, and triglyceride metabolism underscored the hepatocyte-protective phenotype and overall decreased liver damage as seen in mouse models of hepatocyte-selective TSC22D4 loss-of-function. CONCLUSIONS: Together, our data uncover a new connection between targeted depletion of TSC22D4 and intrinsic metabolic processes in progressive liver disease. Hepatocyte-specific reduction of TSC22D4 improves hepatic steatosis and promotes hepatocyte survival via mitochondrial-related mechanisms thus paving the way for targeted therapies. Elsevier 2022-04-01 /pmc/articles/PMC9034319/ /pubmed/35378329 http://dx.doi.org/10.1016/j.molmet.2022.101487 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Wolff, Gretchen Sakurai, Minako Mhamane, Amit Troullinaki, Maria Maida, Adriano Deligiannis, Ioannis K. Yin, Kelvin Weber, Peter Morgenstern, Jakob Wieder, Annika Kwon, Yun Sekar, Revathi Zeigerer, Anja Roden, Michael Blüher, Matthias Volk, Nadine Poth, Tanja Hackert, Thilo Wiedmann, Lena De Angelis Rigotti, Francesca Rodriguez-Vita, Juan Fischer, Andreas Mukthavaram, Rajesh Limphong, Pattraranee Tachikawa, Kiyoshi Karmali, Priya Payne, Joseph Chivukula, Padmanabh Ekim-Üstünel, Bilgen Martinez-Jimenez, Celia P. Szendrödi, Julia Nawroth, Peter Herzig, Stephan Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title_full | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title_fullStr | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title_full_unstemmed | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title_short | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function |
title_sort | hepatocyte-specific activity of tsc22d4 triggers progressive nafld by impairing mitochondrial function |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034319/ https://www.ncbi.nlm.nih.gov/pubmed/35378329 http://dx.doi.org/10.1016/j.molmet.2022.101487 |
work_keys_str_mv | AT wolffgretchen hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT sakuraiminako hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT mhamaneamit hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT troullinakimaria hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT maidaadriano hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT deligiannisioannisk hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT yinkelvin hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT weberpeter hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT morgensternjakob hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT wiederannika hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT kwonyun hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT sekarrevathi hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT zeigereranja hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT rodenmichael hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT bluhermatthias hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT volknadine hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT pothtanja hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT hackertthilo hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT wiedmannlena hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT deangelisrigottifrancesca hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT rodriguezvitajuan hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT fischerandreas hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT mukthavaramrajesh hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT limphongpattraranee hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT tachikawakiyoshi hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT karmalipriya hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT paynejoseph hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT chivukulapadmanabh hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT ekimustunelbilgen hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT martinezjimenezceliap hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT szendrodijulia hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT nawrothpeter hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction AT herzigstephan hepatocytespecificactivityoftsc22d4triggersprogressivenafldbyimpairingmitochondrialfunction |